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Background
History of chloroquine use
From the middle of the 20th century, chloroquine (CQ) and its 
synthetic analogues (e.g. sontoquine and primaquine) have been 
used widely for the prophylaxis and treatment of tropical malaria. 
Empirical studies showed CQ to be one of the most effective 
antimalarial agents, and further molecular adaptations led to the 
development of hydroxychloroquine (HCQ), a less toxic metabolite 
of CQ.[1,2] During World War II, soldiers using chloroquine as 
malaria prophylaxis noticed a significant improvement in their 
skin rashes and inflammatory arthritis. Subsequent studies showed 
chloroquine and its synthetic analogues to be highly efficacious in 
the management of autoimmune conditions such as systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (RA).[1,2]
Management of rheumatic and musculoskeletal diseases
In a 4-year study conducted in the 1950s, CQ was used continuously 
to manage RA.[3] Minimal serious side-effects and a 70% positive 
outcome were seen in the RA patient population. It was shown 
that apart from their effective antimalarial activity, CQ and HCQ 
have immunomodulatory properties that make them ideal for the 
management of autoimmune diseases. During the 1950s, both CQ 
and HCQ were therefore identified as disease-modifying anti-
rheumatic drugs (DMARDs), and since then they have been used to 
treat rheumatic autoimmune diseases, specifically SLE.[3] A  pivotal 
study published in 1991 showed that abruptly stopping HCQ 
treatment in patients with SLE was associated with a doubled risk of 
having an acute disease flare.[4]
The COVID-19 pandemic
Several studies have shown that CQ has the ability to interfere 
with viral growth and transmission, including SARS-CoV-2. Both 
in vitro and in vivo studies have demonstrated that chloroquine 
increases endosomal pH, inhibits viral receptor activity, and 
reduces functionality of the host’s angiotensin-converting enzyme 
2 receptors. [2] All these mechanisms interfere with virus receptor 
binding, which makes CQ a potential and relatively safe agent to 
prevent infection by and transmission of SARS-CoV-2.[5] For this 
reason, CQ was included in COVID-19 pneumonia clinical trials 
in China and showed promising results.[6] An open-label non-
randomised clinical trial by Gautret et al.[7] in 2020 showed that HCQ 
has the ability to reduce viral load in patients infected with COVID-
19, especially when combined with azithromycin. However, a meta-
analysis published in September 2020 concluded that there was no 
convincing evidence that CQ or HCQ improved clinical outcomes in 
COVID-19 pneumonia.[8]
Impact of limited access to CQ in South Africa
The national lockdown in South Africa (SA) starting in March 2020 
included a necessary de-escalation of clinical services, closure of 
outpatient departments and limited access to secondary and tertiary 
medical services for patients, including those with chronic rheumatic 
and musculoskeletal diseases (RMDs). At the same time, with the 
speculation and excessive social media coverage regarding anecdotal 
evidence of a potential beneficial role of CQ in COVID-19 treatment, 
shortages of CQ and HCQ were anticipated. Discontinuation of 
CQ for reasons such as limited availability or limitations in access 
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to healthcare services may lead to acute disease flares, increased 
morbidity, and potentially increased mortality.
Objectives
Morbidity and mortality due to the COVID-19 pandemic, and its 
global impact, are not limited to COVID-19 infections, but affect 
a wider patient population, including those with chronic RMDs. 
The objective of this study was therefore to show that access to CQ 
during the COVID-19 pandemic was limited, leading to an increased 
incidence of flares in patients with chronic RMDs and affecting their 
morbidity and potentially causing mortality.
Methods
An audit was conducted in the Division of Rheumatology, Tygerberg 
Hospital, Cape Town, SA, between 15 November and 15 December 
2020. All patients attending the clinic with an underlying RMD 
who had been using CQ for a minimum of 6 months were included. 
A  questionnaire was completed, including details of the healthcare 
facility where the patient routinely collected their chronic medication, 
and details of problems in accessing chronic medication during the 
12 months preceding their appointment. A flare of the underlying 
condition was based on clinical assessment by the treating clinician 
and application of relevant disease activity indices. Hospitalisation 
and mortality related to a flare were documented. The audit was 
approved by the Health Research Ethics Committee of Stellenbosch 
University (ref. no. N20/11/072_COVID-19) and complied with the 
ethical guidelines and principles of the International Declaration of 
Helsinki.
Results
Of a total of 342 consecutive outpatients screened, 177 had used CQ 
for a minimum of 6 months and were included in the audit. The 
majority of these patients (91%) were female, and the mean (standard 
deviation) age was 48 (13.4) years. The spectrum of RMD diagnoses 
is summarised in Fig. 1.
Our patients attended 56 different community healthcare centres 
(CHCs) prior to their outpatient appointment. These included 
22 different rural clinics as far away as Beaufort West, Nieuwoudtville 
and Villiersdorp. Only 6 patients (3%) routinely collected their 
medication from Tygerberg Hospital, and 5% collected it from a 
private pharmacy. The most frequent CHCs visited were within 
the Khayelitsha Health District (total of 6 different clinics attended 
by 22 patients (12%)) and in Delft (n=16 patients; 9%), Elsiesrivier 
(n=11; 6%) and Kleinvlei (n=10; 6%).
Limited access to CQ was reported by 80% of patients (n=142) for 
a median (interquartile range) period of 4 (1 - 6) months, maximum 
11 months. Shortages were most frequently reported during July 
(72%), August (77%) and September 2020 (76%), coinciding with 
the first peak of the pandemic in SA. Access to CQ was significantly 
more limited than access to other conventional synthetic DMARDs 
(n=8), immunosuppressive therapy (including prednisone) (n=10), 
and other chronic medication (Table 1). Most participants (96.6%) 
reported that CQ was not available at their local CHC. Three patients 
were unable to attend their CHC, while 2 patients had incorrect 
prescriptions. Fifty-two patients (29%) made use of alternative 
means to obtain their medication, including buying medication from 
a private pharmacy, borrowing from a family member or friend, or 
returning to Tygerberg Hospital to collect medication.
In 69 cases (39%), the treating clinician reported the patient to 
have had a flare, based on clinical assessment and relevant disease 
activity indices (Fig. 2). In the majority of cases (86%; n=59/69), the 
Table 1. Limited access to chronic treatment reported in 
patients attending rheumatology outpatient department 
(N=177)








Vitamin D 40 (22.6)
Calcium carbonate 12 (6.8)
Antihypertensive treatment 4 (2.3)
PPI = proton pump inhibitor.









Fig. 1. Spectrum of rheumatic and musculoskeletal conditions of patients 
included in the audit (N=177). (RA = rheumatoid arthritis; SLE = systemic 
lupus erythematosus; Other = dermatomyositis (n=3), systemic sclerosis 
(n=2), primary Sjogren’s syndrome (n=4); undifferentiated connective tissue 
disease (n=5), psoriatic arthritis (n=2), sarcoidosis (n=1), polymyalgia 
rheumatica (n=1); Overlap = RA and SLE/systemic sclerosis (n=2).
Fig. 2. Percentage of patients with limited v. normal access to CQ and 
reported flares of their rheumatic and musculoskeletal disease. (CQ = 
chloroquine.)
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flare was attributed to limited CQ access. Of the 69 patients who had 
a flare, 93% (n=64) had limited access to CQ. The various RMDs with 
limited CQ access and clinician-reported flares are depicted in Table 2.
A single patient was hospitalised for a flare of lupus nephritis.
Discussion
The off-label use of a drug can be a commendable gesture in a setting 
where there is some scientific evidence to support this decision by 
a clinician. The patient should be well informed about the decision, 
and signed consent should be obtained.[9] However, off-label use of a 
drug without compelling scientific evidence is discouraged by the US 
Food and Drug Administration.[10] Reasons for this include inability 
to recruit patients already on the drug for randomised controlled 
trials, as they might be assigned to a placebo; hesitancy of drug 
companies to invest in a drug that is already used for the indication; 
and the increased number of side-effects that are seen with off-label 
prescribed drugs as opposed to on-label prescriptions.[11]
The off-label use of CQ during the first wave of the COVID-19 
pandemic in SA led to an additional disadvantage not described 
by the Congressional Research Service group in the document that 
reviewed the advantages and disadvantages of off-label use of drugs 
in February 2021.[12] This is the shortage of drug supply for patients 
who are taking the drug for an on-label indication. In our study, 
shortages of CQ for patients with RMDs were observed as a result of 
the off-label use of this drug during the first wave of COVID-19 in 
SA beginning in March 2020.
One of the World Health Organization’s Millennium Development 
Goals is to achieve universal health coverage.[13] This principle 
recognises the availability and affordability of health services and 
prescription drugs as a basic human right. The limited availability of 
CQ for patients with chronic RMDs during the first wave of COVID-
19 in SA can therefore be considered a violation of a basic human 
right.[13] Such violations should be taken into consideration in the 
near future as the COVID-19 pandemic continues and other sets of 
drugs are considered for off-label use.
Globally the COVID-19 pandemic has affected governments in 
various areas, including healthcare systems and the economy.[14] Off-
label prescription of CQ led to shortages of this drug for patients with 
RMDs in many countries. In European countries, there was estimated 
to be a 49% shortage of CQ for patients with RMDs.[15] In Canada, 
a range of 50 - 79% in the different provinces was estimated.[16] In 
the USA, HCQ non-compliance among patients with RMDs was 
found to be multifactorial and estimated at 20 - 50%.[17] In 15 Arabic 
countries in the Middle East and North Africa, 47% of patients were 
affected by limited access to HCQ.[18]
The off-label use of CQ and HCQ for the treatment of COVID-
19 in Africa has been an ongoing concern and has been observed 
in many countries across the continent. However, the magnitude 
and the impact of this problem have not been established.[19] Our 
audit delineates the challenges of CQ acquisition and consequences 
of lack of the drug during the COVID-19 pandemic in a cross-
sectional cohort of patients with RMDs in Cape Town, SA. We found 
a significantly higher proportion of patients with limited CQ access 
in comparison with reports from the USA and North Africa, with 
disease flares reported by a clinician in 45% of patients v. 14% of those 
with uninterrupted CQ access (p=0.001).
Study limitations
Only outpatients were questioned in the audit. Patients hospitalised 
during the preceding months were not specifically questioned 
about chloroquine access at the time or included in the analyses. 
Hospitalisation, significant disease flares and associated mortality 
may therefore be underestimated in our analyses.
Conclusions
The off-label use of prescription drugs can lead to shortages of 
the drug for patients who are on the drug for on-label use, as 
demonstrated in our cohort, where a shortage of CQ followed its off-
label use. The shortage of CQ had a significant impact on the disease 
activity of patients with RMDs. Off-label prescription of a widely 
used drug such as CQ should therefore be implemented cautiously 
by clinicians, especially during pandemics, as this may lead to poor 
outcomes for the subset of patients already on the drug in question.
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